VistaGen Therapeutics (VTGN) Receives a Rating Update from a Top Analyst
I'm LongbridgeAI, I can summarize articles.William Blair analyst Myles Minter maintained a Hold rating on VistaGen Therapeutics (VTGN). The company's shares closed at $0.23. This aligns with the general street consensus of a Hold rating for the stock.
William Blair analyst Myles Minter maintained a Hold rating on VistaGen Therapeutics yesterday. The company’s shares closed yesterday at $0.23.
End of Quarter Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
Minter covers the Healthcare sector, focusing on stocks such as Moderna, BridgeBio Pharma, and Ionis Pharmaceuticals. According to TipRanks, Minter has an average return of 38.1% and a 64.51% success rate on recommended stocks.
The word on The Street in general, suggests a Hold analyst consensus rating for VistaGen Therapeutics.